Clinical Trial: A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia

U.S., Dec. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07278830) titled 'A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia' on Dec. 01.

Brief Summary: This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of SAL003, a recombinant fully human anti-PCSK9 monoclonal antibody, in combination with a stable dose of atorvastatin in patients with hypercholesterolemia and mixed dyslipidemia.

Study Start Date: June 02, 2023

Study Type: INTERVENTIONAL

Condition: Hypercholesterolemia and Mixed Dyslipidemia

Intervention: DRUG: SAL003 140mg+Atorvastatin...